Opera Bioscience

Opera Bioscience is an early-stage biotech tools and services company that has developed a proprietary E. coli-based protein secretion platform. This technology aims to deliver soluble, active proteins with high starting purity and lower endotoxin levels, addressing common challenges in protein yield, solubility, and purification cost. The company is currently pre-revenue, developing a library of research-use-only (RUO) cytokines and growth factors for launch in early 2026, while simultaneously offering custom secretion feasibility screening and protein manufacturing services to researchers and developers. Its value proposition centers on reducing the time and expense associated with obtaining high-quality proteins for research and early-stage production.

Proprietary E. coli-based bacterial secretion platform designed to produce soluble, active proteins with high starting purity (up to 90%) and lower endotoxin, simplifying purification.

Opera competes in the broad recombinant protein market against giants like Thermo Fisher Scientific, Bio-Techne, and Merck, as well as numerous specialized CDMOs. Its differentiation hinges on the claimed cost and purity advantages of its proprietary secretion platform, targeting price-sensitive researchers and those struggling with difficult-to-express proteins in standard systems.